ArticleIBRO neuroscience reports2026
Therapeutic potential of edaravone and flurbiprofen in valproic acid-induced autism: Targeting oxidative stress and neuroinflammation.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Autism Spectrum Disorder (ASD) presents significant therapeutic challenges, with growing evidence implicating neuroinflammation and oxidative stress in its pathophysiology. This study aimed to investigate the protective effects of edaravone and flurbiprofen, administered alone and in combination, in a valproic acid (VPA)-induced autism model in male rats. Materials and methods: An autism model was established through prenatal VPA exposure. Social behavior, anxiety, and memory were assessed using a battery of standardized behavioral tests. Pro-inflammatory and oxidative stress markers were evaluated via ELISA, and hippocampal neuronal density was assessed by Nissl staining. Results: All treatment groups (edaravone, flurbiprofen, and their combination) showed significant improvements in autism-related behaviors, including enhanced social interaction, reduced memory deficits, and decreased anxiety. The treatments lowered pro-inflammatory cytokines (IL-6, TNF-α) and MDA levels, while restoring the activity of antioxidant enzymes GPX and SOD. Conclusions: Edaravone and flurbiprofen effectively improved autism-like behaviors by targeting shared pathways of oxidative stress and neuroinflammation. However, the combination therapy offered no additive benefits over monotherapy. This finding suggests that monotherapy with either drug is sufficient to achieve maximal therapeutic effects, a point with significant implications for future treatment strategies in ASD. Significance statement: This study advances neurodevelopmental neuroscience by demonstrating that independently targeting oxidative stress or neuroinflammation achieves maximal behavioral and hippocampal rescue in an autism model, revealing a convergent therapeutic ceiling that challenges combinatorial polypharmacy and refines our understanding of how overlapping pathological pathways govern neural circuit dysfunction and functional recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.